A Plan to Raise 150 Billion Rupees
According to Wednesday's (October 7) announcement, Sun Pharma's board meeting on October 12 will consider issuing non-convertible debentures worth up to 150 billion rupees. At an exchange rate of about 96.67 rupees to the dollar, the fundraising is equivalent to $1.55 billion, placing it among the largest debt issues by an Indian private company this year.
Non-convertible debentures are debt instruments that cannot be converted into shares, allowing companies to raise funds without diluting existing shareholders. In return, the company must pay regular interest and repay principal at maturity, so borrowing costs depend heavily on credit ratings and prevailing interest rates.
The Burden of the Organon Deal
According to Reuters, earlier this year Sun Pharma closed the syndication of a near-$12 billion, 18-month bridge loan to acquire Organon & Co., with several banks taking part, including State Bank of India (SBI). A bridge loan is short-term financing used to fund a deal before being replaced by longer-term funding such as bonds.
















